Moore Capital Management LP Has $24.50 Million Holdings in CVS Health Corporation $CVS

Moore Capital Management LP trimmed its position in CVS Health Corporation (NYSE:CVS) by 13.3% in the third quarter, Holdings Channel reports. The fund owned 325,000 shares of the pharmacy operator’s stock after selling 50,000 shares during the quarter. Moore Capital Management LP’s holdings in CVS Health were worth $24,502,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. increased its holdings in CVS Health by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock worth $8,305,132,000 after purchasing an additional 2,063,737 shares in the last quarter. Capital World Investors boosted its stake in shares of CVS Health by 2.1% during the third quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock valued at $5,155,380,000 after purchasing an additional 1,419,575 shares in the last quarter. State Street Corp grew its holdings in shares of CVS Health by 1.4% during the second quarter. State Street Corp now owns 58,788,585 shares of the pharmacy operator’s stock worth $4,055,237,000 after purchasing an additional 800,414 shares during the last quarter. Capital International Investors increased its stake in shares of CVS Health by 1.1% in the third quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator’s stock valued at $2,012,347,000 after buying an additional 302,499 shares during the period. Finally, Invesco Ltd. raised its holdings in CVS Health by 3.2% in the 3rd quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock valued at $1,831,454,000 after buying an additional 760,579 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Down 0.4%

Shares of NYSE CVS opened at $75.81 on Tuesday. The company’s 50 day moving average price is $78.08 and its 200-day moving average price is $77.85. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84. CVS Health Corporation has a 52-week low of $58.35 and a 52-week high of $85.15. The company has a market capitalization of $96.45 billion, a P/E ratio of 54.94, a price-to-earnings-growth ratio of 0.79 and a beta of 0.49.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The company had revenue of $105.69 billion during the quarter, compared to analysts’ expectations of $103.67 billion. During the same period in the prior year, the company posted $1.19 earnings per share. CVS Health’s revenue for the quarter was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were given a $0.665 dividend. The ex-dividend date of this dividend was Thursday, January 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.5%. CVS Health’s dividend payout ratio (DPR) is 192.75%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CVS. Robert W. Baird boosted their target price on shares of CVS Health from $82.00 to $92.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Truist Financial set a $100.00 price target on shares of CVS Health in a research note on Wednesday, December 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of CVS Health in a report on Wednesday, December 10th. The Goldman Sachs Group increased their price objective on CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a report on Thursday, February 12th. Finally, TD Cowen reaffirmed a “buy” rating on shares of CVS Health in a research report on Friday. Twenty analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, CVS Health presently has an average rating of “Moderate Buy” and an average target price of $95.05.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.